Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
Britain Courts Anthropic Amid US Defense Department Dispute 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
 Securities Case - EconoTimes)
NEW YORK, Dec. 08, 2016 -- Scott+Scott, Attorneys at Law, LLP (“Scott+Scott”), a national investor rights law firm, reminds investors that January 5, 2017 is the last day to file lead plaintiff papers in the securities lawsuit against Teva Pharmaceutical Industries Limited (“Teva” or the “Company”) (NYSE:TEVA). The class action is on behalf of a class consisting of all persons who purchased Teva American Depositary Shares (“ADSs”) between February 10, 2015 and November 3, 2016, both dates inclusive (the “Class Period”). Teva investors are encouraged to go to: http://www.scott-scott.com/cases/new/securities-fraud-litigation-3027-teva-pharmaceutical-industries-limited-teva.html.
Teva primarily develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines. Teva ADSs are traded on the New York Stock Exchange (“NYSE”) under the ticker symbol “TEVA.”
The complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) Teva was involved in and/or had been involved in conduct that would result in an antitrust investigation by the U.S. Department of Justice and the State of Connecticut Office of the Attorney General; (2) the DOJ investigation and the misconduct may instigate U.S. prosecutors to file criminal charges against Teva for alleged price manipulation; (3) as a result, Teva lacked effective internal controls; and (4) consequently, Teva's public statements were materially false and misleading at all relevant times.
What You Can Do
If you purchased Teva ADSs, you may have legal claims against the Company. If you want to discuss filing lead plaintiff papers, or have questions about your legal rights, please contact attorney Joseph Pettigrew at (619) 517-1129, or at [email protected].
About Scott + Scott, Attorneys at Law, LLP
Scott+Scott has significant experience prosecuting major securities, antitrust, and employee retirement plan actions throughout the United States. The firm has offices in New York, London, Connecticut, California, and Ohio. Please visit www.scott-scott.com for more information about the firm.
CONTACT: Joseph Pettigrew Scott+Scott, Attorneys at Law, LLP (619) 517-1129 [email protected]
